ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.

Slides:



Advertisements
Similar presentations
Parkinsons Disease Management in Primary Care. Introduction Progressive condition 1:500 whole population 1:50 of elderly 1:10 Nursing Home Residents.
Advertisements

Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Pharmacology of Drugs Used in Parkinson’s Disease Jose Paciano B.T. Reyes, FPNA ASMPH January 27, 2011.
ILOs At the end of this lecture you will be able to:- Recognize the symptoms and pathophysiology of parkinsonism. Understand the pharmacology of drugs.
ILOs At the end of this lecture you will be able to:- Revew the symptoms and pathophysiology of parkinsonism. Detail on the pharmacology of drugs used.
Drugs for Neurodegenerative Diseases Kaukab Azim, MBBS, PhD.
Parkinson’s Disease (PD)
Pharmacology – II PHL-322 Chapter 4 ANTI-PARKINSONIAN DRUGS
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Presented by Abdulaziz .M. Al-Saad
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
Initial Diagnosis and Management of Parkinson’s Disease
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Objectives Description of Parkinson's disease
Anti Parkinson's Drugs Parkinsonism
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
Drugs of Anti-Parkinson’s disease Department of Pharmacology Zhang Yan-mei.
PARKINSON’S DISEASE. ETIOLOGY 1) Idiopathic 2)Exposure to : neurotoxin Oxidative stress Drugs Oxidative stress Drugs 3)Genetic factors. 3)Genetic factors.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Chapter 31 Anti-Parkinson Agents. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Parkinson’s.
By Prof. Hanan Hagar Pharmacology unit Medical College.
ANTIPSYCHOTIC. What do antipsychotics treat?  Psychotic Disorders (Psychosis) Abnormal Thinking and Perceptions Loss of Contact with Reality Delusions.
Drugs For Parkinson's Disease. History of Parkinson's Disease l First characterized in 1817 by James Parkinson : An Essay On The Shaking Palsy.
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Represented by SHIVAJI SINGH SAMEER CHAVAN SOURIMA MUKHERJEE SONAL KULKARNI SUVARNA CHAVAN M.Sc (CLINICAL RESEARCH) (CRANFIELD)GROUP-9.
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
Drugs used in parkinsonism
By Prof. Hanan Hagar Pharmacology unit Medical College.
By Prof. Hanan Hagar Pharmacology unit Medical College.
1 Copyright © 2012, 2009, 2006, 2003 by Saunders, an imprint of Elsevier Inc. Chapter 23 DRUGS FOR NEUROLOGIC DISORDERS: PARKINSONISM AND ALZHEIMER’S DISEASE.
Parkinson's Disease ILOs
Drugs in parkinsonism ilos
Dr. Laila M. Matalqah Ph.D. Pharmacology PHARMACOLOGY OF CNS part 1 General Pharmacology M212.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Parkinson’s Disease Angela Duncan June Why I Chose This Subject Common neurodegenerative disorder / in Scotland Expected increase.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
 Parkinson’s disease is a neurodegenerative disorder first described by Dr James Parkinson, a London physician, in The underlying cause is loss.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Pharmacological Treatment of Parkinson Disease: A.
Pharmacologic Management of parkinsonism
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Parkinson's disease.
Drugs Used for Parkinson’s Disease
Parkinson’s Disease.
Parkinsonism.
DRUGS FOR PARKINSONISM
Pharmacologic Management of Parkinson disease (PD)
Drugs of Anti-Parkinson’s disease
Drugs used in parkinsonism
Drugs for Parkinson’s Disease
Dallas Wood Dylan griFFin matt Nicholson
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
Parkinsonism: MAO-i, COMT-i and other
Drug-induced dyskinesias
Central Nervous System
Parkinsonism and Anesthesia
מחלת פרקינסון מחלת פרקינסון היא מחלה Progressive.
Anti-parkinsonism Drugs
Anti-parkinsonism Drugs
Antiparkinsonian drugs Presented by K.Lakshmi Department of pharmacology Assistant professor SSPC.
Drugs for Degenerative Diseases of the Nervous System
Classification of Epilepsy (p. 227)
Neurodegenerative diseases
Presentation transcript:

ANTI-PARKINSONIAN DRUGS

Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.

The signs include: rigidity of skeletal muscles. akinesia(or bradykinesia or hypokinesia). flat facies. tremor at rest.

There are two types of parkinsonism: Idiopathic parkinsonism: In which the pathologic characteristics include a decrease in the levels of dopamine and the degeneration of dopaminergic neurons. The reduction of normal dopaminergic neurotransmission leads to excessive excitatory actions of cholinergic neurons,thus dopamine and acetylcholine activities are out of balance in parkinsonism.

Drug induced parkinsonism: Many drugs can cause symptoms of parkinsonism,these effects are usually reversible. The most important are: The butyrophenone and phenothiazine anti-psychotic drugs,which block brain dopamine receptors. Reserpine at high doses causes silimar symptoms,by depleting brain dopamine stores. Cholinesterase inhibitors,by increasing cholinergic activity.

Drug therapy of parkinsonism: Strategies of drug treatment of parkinsonism involve increasing dopamine activity in the brain or decreasing muscarinic cholinergic activity in the brain. It should be noted that parkinsonism is a chronic progressive disease,and that treatment is only symptomatic.

Though treatment does not stop the progress of the disease,it improves the quality and expectancy of life in most patients.

1.Levodopa: Dopamine does not readily cross the blood brain barrier,its precursor levodopa is used,this amino acid is converted to dopamine by the enzyme dopa decarboxylase,which is present in many tissues including the brain.

Levodopa is usually given with carbidopa(dopa decarboxylase inhibitor),a drug that does not cross the blood brain barrier,but inhibits dopa decarboxylase in peripheral tissues. With this combination,lower doses of levodopa are needed(effective) and there are fewer peripheral side effects.

Levodopa is the drug of choice in severe parkinsonism,it can reduce hypokinesia,rigidity and tremor,it is less effective in post-encephalitic parkinsonism and should be avoided in drug induced parkinsonism.

Side effects: G.I.T. anorexia,nausea,vomiting. C.V.S. postural hypotension,tachycardia, asystole,cardiac arrhythmias. dyskinesia.

behavioral: anxiety,agitation,confusion,delusion,hallucinatio- ns,depression. Levodopa may sometimes lose its effectiveness after several months of therapy and the patient experiences marked swings from mobility to total immobility(referred to as on-off effect),this fluctuating disability may last several minutes or hours.

These changes appear to be related to blood levels of dopa,high doses may induce dyskinesia and low doses may induce immobility(akinesia). In the later case(akinesia) increasing the dose frequency may be helpful and adding bromocriptine may be useful.

2.Bromocriptine: It acts as an agonist at dopamine receptors in the brain. It can relieve akinesia,rigidity,and tremor. It is less effective than levodopa but has a longer duration of action and causes less dyskinesia.

It is used as an individual drug, in combination with levodopa(and with anti- cholinergic drugs)and in patients who cannot tolerate levodopa.

Side effects: G.I.T. anorexia,nausea,vomiting. C.V.S. postural hypotension,cardiac arrhythmias. dyskinesia. behavioral:confusion,hallucinations,delusio -ns. miscellaneous: pulmonary infiltrates.

3.Amantadine: Enhances dopaminergic neurotransmission by unknown mechanism that may involve increasing synthesis or release of dopamine or inhibition of reuptake of dopamine,the drug has also muscarinic blocking actions.

Amantadine may improve bradykinesia,rigidity and tremor,but is usually effective for only a few weeks. Amantadine has also anti-viral effects.

Side effects: behavioral: restlessness,agitation,insomnia,confusion, hallucinations and acute toxic psychosis. miscellaneous: G.I.T. disturbances,urinary retention and postural hypotension.also may cause peripheral edema that responds to diuretics.

4.Selegiline: It is a selective inhibitor of MAO type B,which is the enzyme that metabolizes dopamine. Selegiline may increase brain dopamine levels. The drug is used as an adjunct with levodopa in parkinsonism and also has been used as the sole agent in newly diagnosed patient.

Side effects: Insomnia,mood changes,dyskinesia,G.I.T.distress,hypoten -sion.

5.Entacapone and Tolcapone: They are inhibitors of catechol-o-methyl transferase(comt),the enzyme that converts levodopa to 3-o-methyl dopa(3-o-md). Increased plasma levels of (3-o-md) are associated with poor response to levodopa,partly because the compound competes with levodopa for active transport into the C.N.S.

The drugs are used as adjuncts to levodopa-carbidopa,improving and prolonging the response to therapy.

Side effects: Dyskinesia,G.I.T.distress,postural hypotension,hepatic failure.

6.Acetylcholine- blocking(antimuscarinic)drugs: These drugs decrease the excitatory actions of cholinergic neurons by blocking muscarinic receptors.

Drugs such as benztropine or trihexyphenidyl may improve the tremor and rigidity of parkinsonism but have little effect on bradykinesia.

Anti-cholinergics are particularly valuable in the treatment of parkinsonism induced by anti-psychotics(phenothiazines) and metoclopramide and in patients with post- encephalitic parkinsonism.

Side effects:are that of acetylcholine blocking drugs. C.N.S. drowsiness,inattention,confusion,delusions,hallucinations. peripheral: are typical of atropine like drugs.

Anti-cholinergics may be combined with amantadine and in severe cases with levodopa. The dose of anti-cholinergics should be increased gradually(every3-5days) to avoid or minimize the side effects.